MX2011012044A - Compuestos de triazina aromatica sustituida que contienen oligomeros. - Google Patents

Compuestos de triazina aromatica sustituida que contienen oligomeros.

Info

Publication number
MX2011012044A
MX2011012044A MX2011012044A MX2011012044A MX2011012044A MX 2011012044 A MX2011012044 A MX 2011012044A MX 2011012044 A MX2011012044 A MX 2011012044A MX 2011012044 A MX2011012044 A MX 2011012044A MX 2011012044 A MX2011012044 A MX 2011012044A
Authority
MX
Mexico
Prior art keywords
oligomer
substituted aromatic
triazine compounds
containing substituted
aromatic triazine
Prior art date
Application number
MX2011012044A
Other languages
English (en)
Spanish (es)
Inventor
Jennifer Riggs-Sauthier
Bo-Liang Deng
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2011012044A publication Critical patent/MX2011012044A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075Two hetero atoms, in positions 3 and 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2011012044A 2009-05-13 2010-05-13 Compuestos de triazina aromatica sustituida que contienen oligomeros. MX2011012044A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17793109P 2009-05-13 2009-05-13
PCT/US2010/034770 WO2010132691A1 (en) 2009-05-13 2010-05-13 Oligomer-containing substituted aromatic triazine compounds

Publications (1)

Publication Number Publication Date
MX2011012044A true MX2011012044A (es) 2011-12-14

Family

ID=42557491

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012044A MX2011012044A (es) 2009-05-13 2010-05-13 Compuestos de triazina aromatica sustituida que contienen oligomeros.

Country Status (10)

Country Link
US (4) US8772479B2 (enExample)
EP (1) EP2430003B1 (enExample)
JP (1) JP5656980B2 (enExample)
KR (1) KR101799113B1 (enExample)
CN (1) CN102421763B (enExample)
AU (1) AU2010248943B2 (enExample)
CA (1) CA2760219C (enExample)
IL (1) IL216314B (enExample)
MX (1) MX2011012044A (enExample)
WO (1) WO2010132691A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010248943B2 (en) 2009-05-13 2015-05-21 Nektar Therapeutics Oligomer-containing substituted aromatic triazine compounds
US10189859B2 (en) 2013-12-21 2019-01-29 Nektar Therapeutics Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
EA201992474A3 (ru) 2015-02-25 2020-05-31 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Агонисты 5ht для лечения нарушений

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60201A (en) 1979-06-01 1984-05-31 Wellcome Found 3-amino-6-(substituted)phenyl-1,2,4-triazine derivatives,their preparation and pharmaceutical compositions containing them
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
EP1355671A2 (en) * 2000-11-30 2003-10-29 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of triazine derivatives
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
PL1694363T3 (pl) 2003-12-16 2014-07-31 Nektar Therapeutics Monodyspersyjne kompozycje PEGylowanego naloksolu
FR2869907B1 (fr) 2004-05-05 2009-02-13 Fabre Pierre Dermo Cosmetique Derives dimeriques de 5,6-diphenyl-1,2,4-triazine et leurs utilisations
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
EP2266622A3 (en) 2004-08-26 2012-06-20 Piramal Life Sciences Limited Prodrugs containing novel bio-cleavable linkers
US7678551B2 (en) 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US20060115865A1 (en) * 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
WO2007109564A2 (en) 2006-03-17 2007-09-27 University Of Massachusetts Yeast cell particles as oral delivery vehicles for antigens
AU2010248943B2 (en) 2009-05-13 2015-05-21 Nektar Therapeutics Oligomer-containing substituted aromatic triazine compounds

Also Published As

Publication number Publication date
IL216314B (en) 2018-05-31
CN102421763A (zh) 2012-04-18
EP2430003A1 (en) 2012-03-21
JP5656980B2 (ja) 2015-01-21
US8772479B2 (en) 2014-07-08
IL216314A0 (en) 2012-01-31
US20160194294A1 (en) 2016-07-07
AU2010248943A1 (en) 2011-11-10
CA2760219A1 (en) 2010-11-18
US20120122871A1 (en) 2012-05-17
EP2430003B1 (en) 2019-02-27
US20150065706A1 (en) 2015-03-05
US9617228B2 (en) 2017-04-11
US20140256732A1 (en) 2014-09-11
US9266845B2 (en) 2016-02-23
KR20120015311A (ko) 2012-02-21
AU2010248943B2 (en) 2015-05-21
WO2010132691A1 (en) 2010-11-18
US8895553B2 (en) 2014-11-25
CN102421763B (zh) 2015-06-17
JP2012526847A (ja) 2012-11-01
KR101799113B1 (ko) 2017-11-17
CA2760219C (en) 2016-08-16

Similar Documents

Publication Publication Date Title
JOP20180102A1 (ar) مركب صيدلاني
UA107791C2 (en) Pesticidal compositions
EA201270216A1 (ru) Фармацевтический состав
MX2010002285A (es) Combinaciones de principios activos con propiedades insecticidas y acaricidas.
MX2014002014A (es) Formulaciones, uso de las mismas como o para producir detergentes para lavado de vajillas y produccion de las mismas.
GT201400102A (es) 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
IN2012DN02984A (enExample)
NO20083462L (no) Nye tiofenderivater som S1P1/EDG1-reseptoragonister
WO2009099670A3 (en) Oligomer-cannabinoid conjugates
CY1119826T1 (el) Θεραπευτικες συνθεσεις που περιεχουν μακιτεντανη
MY187718A (en) Pharmaceutical formulations
PH12013501481A1 (en) Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease
AR112787A2 (es) Compuestos 1,5-difenil-penta-1,4-dien-3-ona
MX2015002038A (es) Pirazoles sustituidos como bloqueadores del canal de calcio tipo n.
BRPI0914940A8 (pt) Composições nutritivas contendo punicalaginas
MX2009008028A (es) Agentes antiparasitarios.
WO2010132693A3 (en) Oligomer-containing pyrrolidine compounds
MX2011012044A (es) Compuestos de triazina aromatica sustituida que contienen oligomeros.
MX2011007940A (es) Conjugados de oligomero-fenotiazina.
IN2012DN03898A (enExample)
MX2012002580A (es) Compuesto antibacteriano novedoso de hidroxifenilo.
WO2011091410A8 (en) Trpv4 antagonists
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
TR201007106A1 (tr) Sefpodoksim proksetil formülasyonları.
TR201002878A2 (tr) Sefpodoksim proksetil içeren farmasötik bileşimler.

Legal Events

Date Code Title Description
FG Grant or registration